Balancing the gender scales in prescription drug coverage
Do women unfairly pay more for prescriptions? According to Senators Olympia Snow (R-ME) and Harry Reid (D-NV), who introduced the Equity in Prescription Insurance and Contraceptive Coverage Act, they do.
Do women unfairly pay more for prescriptions? According to Senators Olympia Snow (R-ME) and Harry Reid (D-NV), who introduced the Equity in Prescription Insurance and Contraceptive Coverage Act, they do.
The cost of birth control pills is not covered by many large group insurance plans. As a result, women of reproductive age spend 63% more than men on out-of-pocket health costs, said Snow. And that, she insisted, is not fair.
"It is simply not right that while the vast majority of insurers cover prescription drugs, half of large group plans exclude coverage of contraceptives," she said. "...Only one-third cover oral contraceptives."
If passed, the bipartisan bill would prohibit plans offering drug coverage from excluding or restricting benefits for FDA-approved prescription contraceptive drugs or devices. The plans would be required to cover outpatient contraceptive services if they provide benefits coverage for other outpatient services.
In addition, health plans could only impose cost-sharing and deductible requirements for contraceptives or outpatient contraceptive services equal to those imposed for other prescription or outpatient benefits.
The bill, which would take effect on January 1, 1998, would be passed as an amendment to ERISA. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
